CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. 3D PRINTED DRUGS: AN OVERVIEW

3.2.1. Why 3D printed drugs?
3.2.2. Indications

3.2.2.1. Dysphagia: target population
3.2.2.2. Other indications

3.2.3. What to expect?

3.2.3.1. Customized dosage forms

3.2.3.1.1. Color
3.2.3.1.2. Flavor
3.2.3.1.3. Shape
3.2.3.1.4. Personalized medications

3.2.3.2. Release of complex drugs

3.2.4. 3D drug printing technologies

3.2.4.1. Inkjet printing
3.2.4.2. Direct-write
3.2.4.3. Zip dose
3.2.4.4. Thermal inkjet (TIJ) printing
3.2.4.5. Fused deposition modelling (FDM)
3.2.4.6. Powder bed printing
3.2.4.7. Stereolithography (SLA)

3.3. MARKET DYNAMICS

3.3.1. Drivers

3.3.1.1. High demand of instantaneous soluble tablets
3.3.1.2. Increasing prevalence of dysphagia
3.3.1.3. Growing usage of 3D printing
3.3.1.4. Increasing adoption of personalized drugs

3.3.2. Restraints

3.3.2.1. 3D printing could be used to print illegal drugs
3.3.2.2. Stringent government regulations for 3D printed products

3.3.3. Opportunities

3.3.3.1. Growing healthcare infrastructure and increase in healthcare investment in emerging nations
3.3.3.2. Rising awareness about the 3D printing technology

3.3.4. Impact analysis

CHAPTER 4 SPRITAM: 3D PRINTED DRUGS MARKET

4.1. OVERVIEW

4.1.1. Key market trends
4.1.2. Growth factors and opportunities

4.2. MARKET SIZE AND FORECAST
4.3. BY GEOGRAPHY

4.3.1. U.S.

4.3.1.1. Key market trends
4.3.1.2. Growth factors and opportunities
4.3.1.3. Market size and forecast

4.3.2. Rest of World

4.3.2.1. Growth factors and opportunities
4.3.2.2. Market size and forecast

CHAPTER 5 OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY SCENARIO

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. LOW GROWTH SCENARIO

5.2.1. Market size and forecast

5.3. MODERATE GROWTH SCENARIO

5.3.1. Market size and forecast

5.4. HIGH GROWTH SCENARIO

5.4.1. Market size and forecast

CHAPTER 6 OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY REGION

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.4. U.S.
6.2.5. Rest of North America

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.4. UK
6.3.5. Germany
6.3.6. France
6.3.7. Italy
6.3.8. Spain
6.3.9. Rest of Europe

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.4. Japan
6.4.5. China
6.4.6. Australia
6.4.7. Rest of Asia-Pacific

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.4. Brazil
6.5.5. Saudi Arabia
6.5.6. Rest of LAMEA

CHAPTER 7 COMPANY PROFILES

7.1. APRECIA PHARMACEUTICALS COMPANY

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Key strategic moves and developments

7.2. FABRX LTD.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments

7.3. GLAXOSMITHKLINE PLC

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance